Tipelukast is under clinical development by MediciNova and currently in Phase II for Hypertriglyceridemia. According to GlobalData, Phase II drugs for Hypertriglyceridemia have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Tipelukast’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Tipelukast (KCA-757) is under development for the treatment of non-alcoholic steatohepatitis, non-alcoholic fatty liver disease, idiopathic pulmonary fibrosis (IPF) and metabolic syndrome. It is administered orally in the form of tablet. The drug candidate targets leukotriene (LT) receptor, phosphodiesterases 3, 4, phospholipase C, 5-lipoxygenase and thromboxane A2. It was also under development for the treatment of bronchial asthma and interstitial cystitis.
MediciNova is a biopharmaceutical company that focuses on acquiring, and developing novel, small-molecule therapeutics for the treatment of neurological, respiratory, and liver diseases. MediciNova’s developmental pipeline includes core programs for the treatment of fibrotic diseases; neurological disorders; and respiratory diseases. The company’s non-core programs formulations developed for indications include treatment of bronchial asthma; interstitial cystitis; solid tumors; and for the treatment of preterm labor. It has partnerships with various companies such as Angiogene Pharmaceuticals Ltd, Kyorin Pharmaceutical Co Ltd, Kissei Pharmaceutical Co Ltd and Meiji Seika Kaisha Ltd, to develop and commercialize its products. The company is headquartered in La Jolla, California, the US.
For a complete picture of Tipelukast’s drug-specific PTSR and LoA scores, buy the report here.